Real-World Evidence and Access Considerations for Anti-VEGF Therapies in Retinal Vascular Diseases

How anti-VEGF injections reshape wet AMD, DME, and vein occlusion care, preserving vision—plus what real-world access barriers mean for patients.

Real-world anti‑VEGF outcomes lag trials as durability and missed injections matter; learn how evidence guides everyday wet AMD decisions.

Real-world retina data shows how aflibercept 8 mg and faricimab extend anti-VEGF intervals, guiding treat-and-extend for AMD and DME.

Real-world retina data shows aflibercept 8 mg and faricimab extend anti-VEGF intervals and target Ang2/Tie2 for AMD and DME.

Explore how extended anti‑VEGF dosing impacts cost and care burden, plus key evidence gaps and next‑gen targets for AMD, DME and RVO.